Inhibition of Anchorage-Independent Proliferation and G0/G1 Cell-Cycle Regulation in Human Colorectal Carcinoma Cells by 4,7-Dimethoxy-5-Methyl-1,3-Benzodioxole Isolated from the Fruiting Body of Antrodia camphorata

Hsiu-Man Lien, 1 Hsiao-Wei Lin, 2 Ying-Jan Wang, 3 Li-Ching Chen, 4 Ding-Yah Yang, 1 Ya-Yun Lai, 5 and Yuan-Soon Ho 2

1 Department of Chemistry, Tunghai University, Taichung, Taiwan
2 Graduate Institute of Biomedical Technology, Taipei Medical University, Taipei 110, Taiwan
3 Department of Environmental and Occupational Health, National Cheng Kung University Medical College, Tainan, Taiwan
4 Graduate Institute of Neuroscience, Taipei Medical University, Taipei, Taiwan
5 Department of Applied Chemistry, Chung Shan Medical University, Taichung 402, Taiwan

Correspondence should be addressed to
Ya-Yun Lai, yayun819@csmu.edu.tw and Yuan-Soon Ho, hoyuansn@tmu.edu.tw

Received 15 December 2008; Accepted 16 February 2009

Copyright © 2011 Hsiu-Man Lien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this study, 4,7-dimethoxy-5-methyl-1,3-benzodioxole (SY-1) was isolated from three different sources of dried fruiting bodies of Antrodia camphorata (AC). AC is a medicinal mushroom that grows on the inner heartwood wall of Cinnamomum kanehirai Hay (Lauraceae), an endemic species that is used in Chinese medicine for its anti-tumor and immunomodulatory properties. In this study, we demonstrated that SY-1 profoundly decreased the proliferation of human colon cancer cells (COLO 205) through G0/G1 cell-cycle arrest (50–150 μM) and induction of apoptosis (>150 μM). Cell-cycle arrest induced by SY-1 was associated with a significant increase in levels of p53, p21/Cip1 and p27/Kip1, and a decrease in cyclins D1, D3 and A. In contrast, SY-1 treatment did not induce significant changes in G0/G1 phase cell-cycle regulatory proteins in normal human colonic epithelial cells (FHC). The cells were cultured in soft agar to evaluate anchorage-independent colony formation, and we found that the number of transformed colonies was significantly reduced in the SY-1-treated COLO 205 cells. These findings demonstrate for the first time that SY-1 inhibits human colon cancer cell proliferation through inhibition of cell growth and anchorage-independent colony formation in soft agar. However, the detailed mechanisms of these processes remain unclear and will require further investigation.

1. Introduction

Antrodia camphorata (A. camphorate, AC), also called A. cinnamomea, is composed of fruiting bodies, mycelium and spores. It is a parasitic fungus that only grows on the inner heartwood wall of Cinnamomum kanehirai Hay (Lauraceae). AC has been used in traditional Chinese medicine to treat food and drug intoxication, diarrhea, abdominal pain, hypertension, pruritis (skin itch) and liver cancer; however, its biological activities have not been meaningfully investigated to date. Recent studies have demonstrated that AC induces significant apoptosis of HL-60 leukemia cells but not of cultured human endothelial cells [1]. Another study demonstrated that AC extracts may be used as an adjuvant anti-tumor agent for human hepatoma cells (C3A and PLC/PRF/5), which are resistant to most other anti-tumor agents. Anti-tumor effects were assessed by monitoring tumor growth and the survival rate of xenograft nude mice after combined therapy with several anti-tumor agents [2].

Colon cancer affects 50–60 of every 100 000 people in North America and is the second most common cause of cancer-related death, after lung cancer [3]. The current set of options for treating human colon cancer are limited to surgical resection, general chemotherapy, gene therapy and radiation therapy [4–6]. Therefore, investigators continue to search for new therapeutic strategies such as adjuvant
therapies [7]. One approach, as explored in this study, seeks to identify medicinal agents that are capable of arresting the cell cycle and/or activating the cellular apoptotic response in cancerous cells. Our results demonstrate that 4,7-dimethoxy-5-methyl-1,3-benzodioxole (SY-1), isolated from dried fruiting body samples of AC, significantly inhibited the proliferation of COLO 205 cells through G0/G1 cell-cycle arrest and apoptosis. We show that SY-1 inhibits the anchorage-independent proliferation of human COLO 205 tumor cells in soft agar colony formation assays. Our results highlight the molecular mechanisms of the anti-tumor effects as mediated by SY-1.

2. Materials and Methods

2.1. Source of Organism. As shown in Figure 1(a), fruiting body samples were obtained from three different AC sources. Sample a, designated YS-187, was a gift from Yusheng Co., Ltd (Taichung, Taiwan). Sample b was purchased from Shinyi, Nantou County, Taiwan. Sample c, a strain of the fungus A. camphorota (BCRC-36795), was purchased from the Food Industry Research and Development Institute (FIRDI), HsinChu County, Taiwan.

2.2. Plate Cultivation of AC. AC (BCRC-36795) was inoculated in a culture medium of potato dextrose agar composed of 0.4% diced potato extract, 2% glucose and 1.5% agar in distilled water. The whole medium was shaken at 28 ± 1°C in darkness, using a 100-rpm rotary shaker for 14 days. The culture broth was collected and evaporated under reduced pressure. The precipitated residue (fruiting body samples of AC) was lyophilized at −80°C.

2.3. Isolation and Characterization of SY-1 from Fruiting Body Samples of AC. The dried fruiting body samples (sample b, BCRC-36795) were ground into a fine powder with an electrical mill and sequentially extracted with ethyl acetate at 80°C under reflux for 3 h. The methanol extracts were separated by gel filtration and chromatographed on a Sephadex G-25 column (MeOH). The flow rate was 0.5 mL min−1. Each fraction measured 15 mL and was collected by a fraction collector. The fractions were further analyzed using a reverse phase C18 column (Mightysil RP-18 GP 250-10, 5 μM). The mobile phase, at a flow rate of 1.5 mL min−1, consisted of 2% acetic acid and acetonitrile, programmed as follows: 2% acetic acid–acetonitrile (38:62) for 25 min, decreased to 2% acetic acid–acetonitrile (0:100) between the 26th and 55th min, then increased again to 2% acetic acid–acetonitrile (38:62) between the 56th and 70th min. The spectrophotometric detector was set at 252 nm. Retention fractions were collected at 29.85 min and concentrated by evaporation under reduced pressure. Our results revealed that the yields of SY-1 from dried fruiting body samples a, b and c were 2.5, 0.415 and 5.7 mg g−1, respectively. The same fractions were lyophilized to obtain SY-1 (Figure 1(b)). The NMR data of SY-1 is shown as follows: 1H NMR (200 MHz, CDCl3): δ 2.15 (3H, s, CH3), 3.82 (3H, s, OCH3), 3.85 (3H, s, OCH3), 5.91 (2H, s, −CH2−O), 6.27 (1H, s, aromatic H). 13C NMR (50 MHz, CDCl3): δ 15.92 (CH3); 56.85 (OCH3); 59.94 (OCH3); 101.44 (O−CH2−O); 108.72; 123.66; 134.63; 136.51; 138.64; 138.83. MS (M+) m/z 196. Anal. (C10H12O4) C, H.

2.4. Cell Lines, Cell Culture and Cell Growth Curves. The HT 29 (p53 His273 mutant) [8] and COLO 205 (p53 wild type) [9] cell lines were isolated from human colon adenocarcinomas (HSY-1-38 and CCL-222; American Type Culture Collection). The Hep G2 (p53 wild type, ATCC HB-8065) and MDA-MB-231 (mutant p53, ATCC HTB 26) cell lines were derived from a human hepatocellular carcinoma and human mammary gland epithelial adenocarcinoma, respectively [9–12]. The oral squamous cell carcinoma cell line (Ca9-22), bearing a mutant p53 gene, was used as a research model [13]. FHC (CRL-1831; American Type Culture Collection) is a cell line derived from long-term epithelial cell cultures of normal human fetal colonic mucosa [14]. A total of 1 × 10⁴ cells were seeded in a 35 mm Petri dish and treated with SY-1 (75–375 μM) for cell growth proliferation assays.

2.5. Determination of Cell Viability. After treatment with SY-1, cell growth curves were determined at the indicated time points with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.

2.6. Flow Cytometry. COLO 205 cells were synchronized as previously described [15]. The cells were harvested at various times with trypsin-EDTA, washed twice with PBS/0.1% dextrose, and fixed in 70% ethanol at 4°C. Nuclear DNA was stained with a reagent containing propidium iodide (50 μg mL−1) and DNase-free RNase (2 U mL−1) and measured by a fluorescence-activated cell sorter (FACS). The population of nuclei in each phase of the cell cycle was determined using the well-known CellFIT DNA analysis software (Becton Dickenson, San Jose, CA).

2.7. Protein Extraction and Western Blot Analysis. Western blot analysis was performed as previously described [15, 16]. Immunodetection was carried out by probing with appropriate dilutions of specific antibodies at room temperature for 2 h. Anti-p21/Cip1, anti-p27/Kip1, anti-p53, anti-GAPDH monoclonal antibodies (Santa Cruz, Inc., CA, USA) and anti-cyclin D1, anti-cyclin D3, anti-CDK2, anti-CDK4 and anti-cdc 25C monoclonal antibodies (Transduction Laboratories, Lexington, KY) were used at a dilution of 1:1000. Anti-cyclin A polyclonal antibodies (Transduction, San Diego, CA) were used at a dilution of 1:250. The secondary antibodies, alkaline phosphatase-coupled antimouse and anti-rabbit antibody (Jackson, Westgrove, PA), were incubated at room temperature for 1 h at dilutions of 1:5000 and 1:1000, respectively.

2.8. Analysis of Apoptosis. Apoptosis in COLO 205, HT 29 and FCH cells subjected to the various treatments was determined by DNA fragmentation analysis [17]. Genomic DNA was quantified, and equal amounts of DNA sample were electrophoresed in a 2% agarose gel. The DNA was visualized using ethidium bromide staining.
2.9. Soft Agar Cloning Assay. The base layer consisted of 0.9% low-gelling point SeaPlaque agarose (Sigma, St Louis, MO) in complete COLO 205 culture medium. Soft agar consisting of 0.4% SeaPlaque agarose in complete COLO 205 culture medium was mixed with $1 \times 10^4$ COLO 205 cells and plated on top of the base layer in a culture dish of 60 mm diameter. Soft agar cultures were maintained at 37°C and observed with a Leica DMI 4000B Microscope Imaging System to evaluate colony counts.

2.10. Statistics. All data are reported as means ± SE. Comparisons were subjected to one-way analysis of variance (ANOVA) followed by Fisher’s least significant difference test. Significance was defined as $P < .05$.

3. Results

3.1. Isolation of SY-1 from AC and Its Structural Characterization. As seen in Figure 1(a), three different sources of AC were isolated via extensive chromatographic purification of the ethyl acetate-soluble fraction of the dried fruiting body (Figure 1(a), samples a–c). One major peak was seen for each sample (indicated as compound 1, C1). The chemical structure of the purified white powder (C1) was elucidated by NMR spectroscopy and mass spectrometry studies and was identified as SY-1 (Figure 1(b)). The cells were cultured for 3 days with or without SY-1 (75–375 μM) and were then harvested and counted. Our results suggest that SY-1 (>150 μM) significantly inhibited cell growth in COLO 205 and HepG2 cells in a dose- and time-dependent manner (Figures 2(a) and 2(f)). However, inhibition of the cancer lines HT-29, MDA-MB-231 and Ca9-22 as well as normal (FHC) cells only occurred at higher concentrations of SY-1 (>375 μM) (Figures 2(b), 2(c), 2(d) and 2(e)). These results suggest that the wild-type p53 cancer cells were more sensitive to SY-1 treatment than cancer cells with mutated p53 were.

The yield of SY-1 from dried fruiting body samples (sample b, BCRC-36795) was 0.415 mg g$^{-1}$. To evaluate the anti-proliferative effects of SY-1, isolated from crude extracts of AC, an equal concentration of SY-1 from AC extracts was applied to COLO 205 cells and the cytotoxicity assay was performed (Figure 3(a)). A concentration of greater than 150 μM SY-1 significantly induced cytotoxicity in COLO 205 cells, but lower concentrations had no cytotoxic effects (Figure 3(a), upper panel). However, significant cytotoxic effects was observed in COLO 205 cells treated with 36 mg mL$^{-1}$ of AC crude extract which contained an identical concentration of 75 μM SY-1 (Figure 3(a), lower panel). We next investigated whether the cytotoxic effect of SY-1 on COLO 205 cells was due to apoptotic cell death. SY-1-induced apoptosis was evaluated by DNA fragmentation analysis. As shown in Figure 3(b), DNA fragmentation was only observed in the SY-1-treated COLO 205 cells (>150 μM). In contrast, DNA fragmentation induced by a higher dose of SY-1 (225 μM) was not observed in either the HT 29 or FCH cells (Figure 3(c)). These results suggest that
Figure 2: Dose-dependent effects of SY-1 on cell growth in malignant and normal human cells. (a) COLO 205, (b) HT 29, (c) normal human colonic epithelial (FHC), (d) MDA-MB-231, (e) Ca9-22 and (f) Hep G2 cells were treated with various concentrations of SY-1 (75–375 μM). Media with or without SY-1 was renewed daily prior to cell counting. Three samples were analyzed in each group. Values represent mean ± SE.
SY-1-induced apoptosis, as observed in the COLO 205 cells, occurs in a cell-specific manner.

3.3. Arrest of Cell Cycle at the G0/G1 Phase by SY-1 in Human COLO 205 Cells. As shown in Figure 2(a), concentrations of SY-1 ranging from 75 to 350 μM induced a dose-dependent inhibition of cell growth in human COLO 205 cancer cells. We further demonstrated significant apoptosis at doses greater than 150 μM (Figure 3(b)). These results imply that lower doses of SY-1 (<150 μM) should affect the cell cycle. To more clearly demonstrate the actions of SY-1 during a specific phase of the cell cycle, the COLO 205 cancer cells were synchronized by switching them to media that contained 0.04% FCS for 24 h to render them quiescent [15]. Subsequently, the cells were returned to culture media containing 10% FCS and 0.05% DMSO with or without 150 μM SY-1. The cells were harvested for flow cytometry analysis of DNA content at various times thereafter (Figure 4(a)). The results demonstrate that SY-1 induced an accumulation of greater than 85% of COLO 205 cells at the G0/G1 phase of the cell cycle, suggesting that the observed growth inhibitory effect of SY-1 was due to an arrest at the G0/G1 phase of the cell cycle.

Figure 4(b) demonstrates the dose effects of SY-1 on G0/G1 arrest. According to our previous studies [18, 19] and the representative FACS analysis (Figure 4(a), left panel), 0, 15, 21 and 24 h represent the G0/G1, S, G2/M and 2nd G0/G1 phases, respectively. The greatest difference in the G0/G1 cell populations of the SY-1-treated and control groups was recorded at 15 h after replacement with complete medium. Accordingly, this time point was selected to study the dose-dependent effect of SY-1 and to identify the minimal dose of SY-1 required for induction of G0/G1 arrest, as determined by flow cytometry analysis. As illustrated in Figure 4(b), significant G0/G1 arrest in COLO 205 cells was induced by treatment with SY-1 (>50 μM) in a dose-dependent manner. We further demonstrated that the Sub-G1 (apoptotic) population of COLO 205 cells was significantly increased by exposure to more than 150 μM SY-1 for 15 h.

3.4. The Effects of SY-1 on G0/G1 Phase Cell-Cycle Regulatory Proteins. To investigate the underlying molecular mechanisms of SY-1-induced G0/G1 arrest, the COLO 205 cells were switched to media with 0.04% FCS to render them quiescent at the G0/G1 phase. They were then returned to culture media supplemented with 10% FCS and 0.05%
Figure 4: Time- and dose-dependent SY-1-induced G0/G1 phase arrest and apoptosis in COLO 205 cells. (a) COLO 205 cells were synchronized with 0.04% FCS for 24 h as described in “Materials and Methods” section. After synchronization, the cells were released into complete medium (10% FCS) containing 0.05% DMSO (left panel), or 150 μM SY-1 in 0.05% DMSO (right panel). The percentages of cells in the Sub-G1, G0/G1, S and G2/M phases of the cell cycle were determined using the well-known CellFIT DNA analysis software. Three samples were analyzed in each group, and values represent the mean ± SE (b). Dose-dependent effects of SY-1 on cell cycle and apoptosis in human cancer cells. FACS analysis of DNA content 15 h after release from quiescence by incubation in culture media supplemented with 10% FCS and various concentrations of SY-1 in 0.05% DMSO. The percentage of cells in the Sub-G1, G0/G1, S and G2/M phases of the cell cycle were determined using the CellFIT DNA analysis software. Three samples were analyzed in each group, and values represent the mean ± SE.

DMSO with or without SY-1 (75–225 μM). After 15 h they were harvested for protein extraction and western blot analysis to examine the effects of SY-1 on the expression of G0/G1 phase cell-cycle regulatory proteins.

Recent studies have demonstrated that the cyclin-dependent kinase (CDK) inhibitors, including p21/Cip1 and p27/Kip1, are up-regulated in human cancer cells arrested in G0/G1 by treatment with anti-cancer agents [20, 21]. Our previous study showed that the protein levels of p21/Cip1 and p27/Kip1 were increased in the quiescent COLO 205 cells and then decreased 15 h after release from quiescence [22]. Similar results were observed in our present study. The protein levels of p21/Cip1 and p27/Kip1 were lower at 15 h after the addition of 10% FCS medium (Figure 5, right panel, lane 1). In contrast, increased p21/Cip1 and p27/Kip1 protein levels were induced in the SY-1 (>70 μM)-treated COLO 205 cells (Figure 5, right panel, lanes 2–4). The levels of cyclins A, D1 and D3 were down-regulated in the SY-1-treated cells, while the levels of CDK2 and CDK4 proteins did not change (Figure 5, right panel, lanes 2–4). Cdc 25C, which promotes cell entry into the S and the G2/M phases, was also down-regulated at a higher SY-1 dose (>225 μM) (Figure 5,
Figure 5: Dose effect of SY-1 on the concentrations of cell-cycle regulatory proteins. Normal human colonic epithelial (FHC, left panel) and cancer (COLO 205, right panel) cells were rendered quiescent for 24 h and then given 10% FCS in the presence or absence of SY-1 (75–150 μM) for an additional 15 h. Protein extracts (100 μg/lane) were separated by SDS-PAGE, probed with specific antibodies and detected using the nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate systems. Membranes were also probed with an anti-GAPDH antibody to correct for differences in protein loading.

In contrast to normal adherent cells, tumor cells have the ability to grow without binding to a substrate. Our data suggests that anchorage-independent proliferation is a hallmark of tumor cell malignancy [25]. The anchorage-independent proliferation of COLO 205 cells was investigated in soft agar colony formation assays (Figure 6). Twelve days after plating, both the control and SY-1-treated COLO 205 cells showed colony formation in medium containing 0.3% agar. As shown in Figure 6(a), the average sizes of the control COLO 205 colonies were 2-3 times larger than the SY-1-treated group. Compared to the DMSO-treated control cells, SY-1 (>75 μM) significantly reduced the number of colonies formed in a dose-dependent manner (Figure 6(b), lanes 2–5).

4. Discussion

The present study was undertaken to investigate the anticancer mechanisms of SY-1 isolated from three different sources of dried fruiting bodies from the Chinese medicinal mushroom, *Antrodia camphorate* (Figure 7). Previous studies have demonstrated that AC induces significant apoptotic cell death in human leukemia (HL-60) [27], breast (MCF-7 and MDA-MB-231) [27, 28], prostate (LNCaP and PC3) [29] and liver (Hep G2, C3A and PLC/PRF/5) cancer cells [2, 30]. Such an effect has never been detected with cultured human endothelial cells [1]. The anti-proliferative effects of AC were also reported in different types of
human cancer cells including breast [27, 28], prostate [29], bladder [31], lung [32] and hepatoma [2]. These results demonstrate that both cell-cycle inhibition and apoptotic cell death contribute to the anti-tumor effects of AC. In a previous paper [33], three purified compounds were isolated from AC, namely sesquiterpenoid lactone (antrocin), SY-1 and 2,2',5,5'-tetramethoxy-3,4,3'-bimethylenedioxypiperidino-6,6'-dimethylphenyl. To our knowledge, ours is the first demonstration that a purified compound (SY-1), isolated from AC, inhibits the cell growth of COLO 205 cells through arrest of the cell cycle and activation of the cellular apoptotic response.

In this study, the inhibitory effect of SY-1 on cell growth appears to be limited to COLO 205 and Hep G2 cells, since similar effects were not observed in other transformed colon cancer (HT 29) cells (Figure 2). Treatment of COLO 205 cells with SY-1 resulted in an increase in the levels of p21/Cip1, p27/Kip1 and p53 proteins, and a decrease in the levels of cyclins A, D1 and D3 (Figure 5). Among these changes, p53 seems to have a major role in SY-1-induced G0/G1 arrest in COLO 205 cells (Figure 7). It seems that SY-1 exerts its anti-tumor activity through cell-cycle arrest or activation of the cellular apoptotic response, depending on the p53 status. A previous report demonstrated that HT-29 cells contain a point mutation at codon 273 (Arg→His) of the p53 gene [8], making it a less efficient inducer of apoptosis [34]. On the other hand, over-expression of mutant p53 is a common theme in human tumors, suggesting a tumor-promoting gain-of-function associated with mutant p53 [35]. A recent study demonstrated that knockdown of mutant p53 sensitizes human colon tumor cells to growth suppression under the activity of various chemotherapeutic drugs [35]. Such results suggest that COLO 205 cells that contain wild-type p53 are susceptible to SY-1-mediated anti-tumor effects. Moreover, SY-1-induced G0/G1 cell-cycle regulatory proteins did not change significantly in the normal colonic cells, namely FHC (Figure 5, left panel). Additional signals, other than p53, may be involved in COLO 205, but are not involved with FHC cells.

Human colon cancer cells often respond in only a limited manner to the currently available chemotherapeutics due to the expression of multidrug resistance genes [36]. Indeed, human cancer cells with mutant p53 seem to activate the promoters of genes that are not usually activated by wild-type p53 protein, such as multidrug resistance gene 1 (MDR1) and c-MYC [37]. Such results suggest that combination therapy is one potential strategy for reducing a compound’s undesirable toxic effect while still maintaining or enhancing its anti-tumor efficacy. In the present study, our results demonstrate that SY-1 inhibits colon cancer cell growth in the G0/G1 phase, induces apoptosis and inhibits colony formation in COLO 205, but not in HT 29 cells. Recent epidemiologic and laboratory investigations suggest that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) exhibit chemopreventive effects against colon cancer, perhaps due, at least in part, to their activity against cyclooxygenase-2 (COX-2) [38]. In addition, induction of apoptosis by AC, through inhibition of COX-2, has also been reported in human breast cancer cells (MDA-MB-231) [27]. In vivo studies have demonstrated that AC extract treatment of human hepatoma cells (C3A and PLC/PRF/5) inhibits MDR gene expression and the pathway of COX-2-dependent inhibition of p-AKT to induce apoptosis [2]. To our knowledge, COX-2 is strongly expressed in all metastatic cell lines (HT-29) but not in non-metastatic lines (COLO 205) [39]. These results imply that AC-mediated COX-2 inhibition is important for inhibition of colon cancer cell growth. However, our results demonstrate that inhibition of cell growth in the HT 29 cells was less profound than in COLO 205 cells (Figure 2), indicating that SY-1, although isolated from AC, may not exert its anti-tumor effects completely through the inhibition of COX-2. In summary, although animal studies of SY-1-induced anti-tumor activity
are still ongoing, the findings from the present in vitro study suggest the potential applications of SY-1 in the treatment of human cancer. The universality of SY-1 in the inhibition of cancer cell proliferation makes it an attractive agent for chemotherapy.

**Funding**

National Science Council of R.O.C. (NSC 96-2628-B-038-003-MY3, NSC 95-2320-B-038-016-MY3 to Y.-S.H. and NSC 96-2320-B-040-010 to Y.-Y.L.).

**References**

[1] Y.-C. Hseu, H.-L. Yang, Y.-C. Lai, J.-G. Lin, G.-W. Chen, and Y.-H. Chang, “Induction of apoptosis by Antrodia camphorata in human premyelocytic leukemia HL-60 cells,” *Nutrition and Cancer*, vol. 48, no. 2, pp. 189–197, 2004.

[2] C.-Y. Chang, Z.-N. Huang, H.-H. Yu et al., “The adjuvant effects of Antrodia Camphorata extracts combined with anti-tumor agents on multidrug resistant human hepatoma cells,” *Journal of Ethnopharmacology*, vol. 118, no. 3, pp. 387–395, 2008.

[3] A. Figueredo, M. E. Coombes, and S. Mukherjee, “Adjuvant therapy for completely resected stage II colon cancer,” *Cochrane Database of Systematic Reviews*, vol. 16, Article ID CD005390, 2008.

[4] T. Kuwai, T. Nakamura, T. Sasaki et al., “Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy,” *Clinical and Experimental Metastasis*, vol. 25, no. 4, pp. 477–489, 2008.

[5] R. Durai, S. Y. Yang, A. M. Seifalian, and M. C. Winslet, “Principles and applications of gene therapy in colon cancer,” *Journal of Gastrointestinal and Liver Diseases*, vol. 17, no. 1, pp. 59–67, 2008.

[6] T. R. Asmis and L. Saltz, “Systemic therapy for colon cancer,” *Gastroenterology Clinics of North America*, vol. 37, no. 1, pp. 287–295, 2008.

[7] C. Kurkjian, A. J. Murgo, and S. Kummar, “Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy,” *Clinical Colorectal Cancer*, vol. 7, no. 5, pp. 321–324, 2008.

[8] D. Niewolik, B. Vojtesek, and J. Kovarik, “p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence,” *Oncogene*, vol. 10, pp. 881–890, 1995.

[9] Y.-S. Ho, Y.-J. Wang, and J.-K. Lin, “Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their...
association with apoptosis in human cancer cells,” *Molecular Carcinogenesis*, vol. 16, no. 1, pp. 20–31, 1996.

[10] L. Hui, Y. Zheng, Y. Yan, J. Bargonetti, and D. A. Foster, “Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D,” *Oncogene*, vol. 25, no. 55, pp. 7305–7310, 2006.

[11] B. Bressac, K. M. Galvin, T. J. Liang, K. J. Isselbacher, J. R. Wands, and M. Ozturk, “Abnormal structure and expression of p53 gene in human hepatocellular carcinoma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 5, pp. 1973–1977, 1990.

[12] B. B. Knowles, C. C. Howe, and D. P. Aden, “Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen,” *Science*, vol. 209, pp. 497–499, 1980.

[13] Y. Imai, K. Ohnishi, J. Yasumoto, A. Kajiwara, N. Yamakawa, A. Takahashi et al., “Glyceral enhances radiosensitivity in a human oral squamous cell carcinoma cell line (Ca-9-22) bearing a mutant p53 gene via Bax-mediated induction of apoptosis,” *Oral Oncology*, vol. 41, pp. 631–636, 2005.

[14] K. M. Siddiqui and D. P. Chopra, “Primary and long term epithelial cell cultures from human fetal normal colonic mucosa,” *In Vitro*, vol. 20, no. 11, pp. 859–868, 1984.

[15] R.-J. Chen, W.-S. Lee, Y.-C. Liang et al., “Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines,” *Toxicology and Applied Pharmacology*, vol. 169, no. 2, pp. 132–141, 2000.

[16] W.-S. Lee, M. K. Jain, B. M. Arkonac et al., “Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines,” *Circulation Research*, vol. 82, no. 8, pp. 845–851, 1998.

[17] Y.-S. Ho, Y.-J. Wang, and J.-K. Lin, “Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells,” *Molecular Carcinogenesis*, vol. 16, no. 1, pp. 20–31, 1996.

[18] W.-S. Lee, R.-J. Chen, Y.-J. Wang et al., “In vitro and in vivo studies of the anticancer action of terbinafine in human colon cancer cells: G0/G1 p53-associated cell cycle arrest,” *International Journal of Cancer*, vol. 106, no. 1, pp. 125–137, 2003.

[19] Y.-S. Ho, C.-H. Wu, H.-M. Chou et al., “Molecular mechanisms of ecomazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways,” *Food and Chemical Toxicology*, vol. 43, no. 10, pp. 1483–1495, 2005.

[20] O. H. Krämer, S. K. Knauer, D. Zimmermann, R. H. Stauber, and T. Heinkel, “Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis,” *Oncogene*, vol. 27, no. 6, pp. 732–740, 2008.

[21] K. Takagi, Y. Sowa, O. M. Cevik, R. Nakanishi, and T. Sakai, “CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells,” *International Journal of Oncology*, vol. 32, no. 5, pp. 1105–1110, 2008.

[22] C.-H. Wu, J.-H. Jeng, J.-Y. Wang et al., “Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest,” *Toxicology and Applied Pharmacology*, vol. 180, no. 1, pp. 22–35, 2002.

[23] L. J. Ko and C. Prives, “p53: puzzle and paradigm,” *Genes and Development*, vol. 10, no. 9, pp. 1054–1072, 1996.

[24] A. J. Levine, “p53, the cellular gatekeeper for growth and division,” *Cell*, vol. 88, no. 3, pp. 323–331, 1997.

[25] M. Takahashi, M. Furihata, N. Akimitsu et al., “A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1,” *Clinical & Experimental Metastasis*, vol. 25, pp. 517–529, 2008.

[26] J. Mei, H. Hu, M. McIntee, H. Plummer III, P. Song, and H.-C. R. Wang, “Transformation of non-cancerous human breast epithelial cell line MCF10A by the tobacco-specific carcinogen NNK,” *Breast Cancer Research and Treatment*, vol. 79, no. 1, pp. 95–105, 2003.

[27] Y.-C. Hseu, S.-C. Chen, P.-C. Tsai et al., “Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorata,” *Food and Chemical Toxicology*, vol. 45, no. 7, pp. 1107–1115, 2007.

[28] H.-L. Yang, C.-S. Chen, W.-H. Chang et al., “Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata,” *Cancer Letters*, vol. 231, no. 2, pp. 215–227, 2006.

[29] C.-M. Ho, C.-C. Huang, C.-H. Huang et al., “Effects of antrodia camphorata on viability, apoptosis, and [Ca2+]i in PC3 human prostate cancer cells,” *Chinese Journal of Physiology*, vol. 51, no. 2, pp. 78–84, 2008.

[30] T. Y. Song, S. L. Hsu, C. T. Yeh, and G. C. Yen, “Mycelia from Antrodia camphorata in Submerged culture induce apoptosis of human hepatoma HepG2 cells possibly through regulation of Fas pathway,” *Journal of Agricultural and Food Chemistry*, vol. 53, pp. 5559–5564, 2005.

[31] C.-C. Peng, K.-C. Chen, R. Y. Peng, C.-H. Su, and H. M. Hsieh-Li, “Human urinary bladder cancer T24 cells are susceptible to the Antrodia camphorata extracts,” *Cancer Letters*, vol. 243, no. 1, pp. 109–119, 2006.

[32] J.-J. Chen, W.-J. Lin, C.-H. Liao, and P.-C. Shieh, “Anti-inflammatory benzenoids from Antrodia camphorata,” *Journal of Natural Products*, vol. 70, no. 6, pp. 989–992, 2007.

[33] C. H. Chiang, W. De-Peng, I. W. Cherng, and U. C. Chueng-Her, “A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea,” *Phytochemistry*, vol. 39, no. 3, pp. 613–616, 1995.

[34] S. Rowan, R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren et al., “Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant,” *EMBO Journal*, vol. 15, pp. 827–838, 1996.

[35] W. Yan, G. Liu, A. Scoumanne, and X. Chen, “Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations,” *Cancer Research*, vol. 68, no. 16, pp. 6789–6796, 2008.

[36] A. Gradilone, F. M. Pulcinelli, L. V. Lotti et al., “Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy,” *Current Cancer Drug Targets*, vol. 8, no. 5, pp. 414–420, 2008.

[37] M. W. Frazier, X. He, J. Wang, Z. Gu, J. L. Cleveland, and G. P. Zambetti, “Activation of c-myec gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain,” *Molecular and Cellular Biology*, vol. 18, no. 7, pp. 3735–3743, 1998.

[38] R. E. Harris, J. Beebe-Donk, and G. A. Alshafie, “Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors,” *BMC Cancer*, vol. 8, article 237, 2008.

[39] T. Yamauchi, M. Watanabe, H. Hasegawa et al., “The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer,” *Anticancer Research*, vol. 23, no. 1, pp. 245–249, 2003.